Ändra sökning
Länk till posten
Permanent länk

Direktlänk
Publikationer (10 of 35) Visa alla publikationer
Revol, R., Koistinen, N. A., Menon, P. K., Chicote-Gonzalez, A., Iverfeldt, K. & Ström, A.-L. (2023). Alpha-secretase dependent nuclear localization of the amyloid-β precursor protein-binding protein Fe65 promotes DNA repair. Molecular and Cellular Neuroscience, 127, Article ID 103903.
Öppna denna publikation i ny flik eller fönster >>Alpha-secretase dependent nuclear localization of the amyloid-β precursor protein-binding protein Fe65 promotes DNA repair
Visa övriga...
2023 (Engelska)Ingår i: Molecular and Cellular Neuroscience, ISSN 1044-7431, E-ISSN 1095-9327, Vol. 127, artikel-id 103903Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Fe65 is a brain enriched adaptor protein involved in various cellular processes, including actin cytoskeleton regulation, DNA repair and transcription. A well-studied interacting partner of Fe65 is the transmembrane amyloid-beta precursor protein (APP), which can undergo regulated intramembrane proteolysis (RIP). Following beta and gamma-secretase-mediated RIP, the released APP intracellular domain (AICD) together with Fe65 can translocate to the nucleus and regulate transcription. In this study, we investigated if Fe65 nuclear localization can also be regulated by different alpha-secretases, also known to participate in RIP of APP and other transmembrane proteins. We found that in both Phorbol 12-myristate 13-acetate and all-trans retinoic acid differentiated neuroblastoma cells a strong negative impact on Fe65 nuclear localization, equal to the effect observed upon gamma-secretase inhibition, could be detected following inhibition of all three (ADAM9, ADAM10 and ADAM17) alpha-secretases. Moreover, using the comet assay and analysis of Fe65 dependent DNA repair associated posttranslational modifications of histones, we could show that inhibition of alpha-secretase-mediated Fe65 nuclear translocation resulted in impaired capacity of the cells to repair DNA damage. Taken together this suggests that alpha-secretase processing of APP and/or other Fe65 interacting transmembrane proteins play an important role in regulating Fe65 nuclear translocation and DNA repair.

Nyckelord
Alzheimer's disease, Amyloid-beta precursor protein, Alpha-secretase, Fe65, DNA repair
Nationell ämneskategori
Medicinska och farmaceutiska grundvetenskaper
Identifikatorer
urn:nbn:se:su:diva-224644 (URN)10.1016/j.mcn.2023.103903 (DOI)001111878900001 ()37918552 (PubMedID)2-s2.0-85175725796 (Scopus ID)
Tillgänglig från: 2023-12-19 Skapad: 2023-12-19 Senast uppdaterad: 2023-12-19Bibliografiskt granskad
Koistinen, N. A., Edlund, A. K., Menon, P. K., Ivanova, E. V., Bacanu, S. & Iverfeldt, K. (2017). Nuclear localization of amyloid-beta precursor protein-binding protein Fe65 is dependent on regulated intramembrane proteolysis. PLOS ONE, 12(3), Article ID e0173888.
Öppna denna publikation i ny flik eller fönster >>Nuclear localization of amyloid-beta precursor protein-binding protein Fe65 is dependent on regulated intramembrane proteolysis
Visa övriga...
2017 (Engelska)Ingår i: PLOS ONE, E-ISSN 1932-6203, Vol. 12, nr 3, artikel-id e0173888Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Fe65 is an adaptor protein involved in both processing and signaling of the Alzheimer-associated amyloid-beta precursor protein, APP. Here, the subcellular localization was further investigated using TAP-tagged Fe65 constructs expressed in human neuroblastoma cells. Our results indicate that PTB2 rather than theWWdomain is important for the nuclear localization of Fe65. Electrophoretic mobility shift of Fe65 caused by phosphorylation was not detected in the nuclear fraction, suggesting that phosphorylation could restrict nuclear localization of Fe65. Furthermore, both ADAM10 and gamma-secretase inhibitors decreased nuclear Fe65 in a similar way indicating an important role also of alpha-secretase in regulating nuclear translocation.

Nationell ämneskategori
Biokemi och molekylärbiologi
Forskningsämne
neurokemi med molekylär neurobiologi
Identifikatorer
urn:nbn:se:su:diva-143465 (URN)10.1371/journal.pone.0173888 (DOI)000399089000040 ()28323844 (PubMedID)
Tillgänglig från: 2017-06-02 Skapad: 2017-06-02 Senast uppdaterad: 2022-03-23Bibliografiskt granskad
Ivanova, E. V., Figueroa, R. A., Gatsinzi, T., Hallberg, E. & Iverfeldt, K. (2016). Anchoring of FRET Sensors-A Requirement for Spatiotemporal Resolution. Sensors, 16(5), Article ID 703.
Öppna denna publikation i ny flik eller fönster >>Anchoring of FRET Sensors-A Requirement for Spatiotemporal Resolution
Visa övriga...
2016 (Engelska)Ingår i: Sensors, E-ISSN 1424-8220, Vol. 16, nr 5, artikel-id 703Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

FRET biosensors have become a routine tool for investigating mechanisms and components of cell signaling. Strategies for improving them for particular applications are continuously sought. One important aspect to consider when designing FRET probes is the dynamic distribution and propagation of signals within living cells. We have addressed this issue by directly comparing an anchored (taFS) to a non-anchored (naFS) cleavable FRET sensor. We chose a microtubule-associated protein tau as an anchor, as microtubules are abundant throughout the cytosol of cells. We show that tau-anchored FRET sensors are concentrated at the cytoskeleton and enriched in the neurite-like processes of cells, providing high intensity of the total signal. In addition, anchoring limits the diffusion of the sensor, enabling spatiotemporally resolved monitoring of subcellular variations in enzyme activity. Thus, anchoring is an important aspect to consider when designing FRET sensors for deeper understanding of cell signaling.

Nyckelord
apoptosis, caspase, FRET sensor, live cell imaging, neurodegeneration, signal transduction
Nationell ämneskategori
Biologiska vetenskaper Biomedicinsk laboratorievetenskap/teknologi Analytisk kemi
Identifikatorer
urn:nbn:se:su:diva-132518 (URN)10.3390/s16050703 (DOI)000378510400074 ()
Tillgänglig från: 2016-08-15 Skapad: 2016-08-15 Senast uppdaterad: 2022-03-23Bibliografiskt granskad
Koistinen, N. A., Bacanu, S. & Iverfeldt, K. (2016). Phosphorylation of Fe65 amyloid precursor protein-binding protein in response to neuronal differentiation. Neuroscience Letters, 613, 54-59
Öppna denna publikation i ny flik eller fönster >>Phosphorylation of Fe65 amyloid precursor protein-binding protein in response to neuronal differentiation
2016 (Engelska)Ingår i: Neuroscience Letters, ISSN 0304-3940, E-ISSN 1872-7972, Vol. 613, s. 54-59Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Fe65 is a brain enriched multi domain adaptor protein involved in diverse cellular functions. One of its binding partners is the amyloid-beta (A beta) precursor protein (APP), which after sequential proteolytic processing by secretases gives rise to the Alzheimer's A beta peptide. Fe65 binds to the APP intracellular domain (AICD). Several studies have indicated that Fe65 binding promotes the amyloidogenic processing of APP. It has previously been shown that expression of APP increases concomitantly with a shift of its processing to the non-amyloidogenic pathway during neuronal differentiation. In this study we wanted to investigate the effects of neuronal differentiation on Fe65 expression. We observed that differentiation of SH-SY5Y human neuroblastoma cells induced by retinoic acid (RA), the phorbol ester PMA, or the gamma-secretase inhibitor DAPT resulted in an electrophoretic mobility shift of Fe65. Similar effects were observed in rat PC6.3 cells treated with nerve growth factor. The electrophoretic mobility shift was shown to be due to phosphorylation. Previous studies have shown that Fe65 phosphorylation can prevent the APP-Fe65 interaction. We propose that phosphorylation is a way to modify the functions of Fe65 and to promote the non-amyloidogenic processing of APP during neuronal differentiation.

Nyckelord
Fe65, Neuroblastoma cells, Phorbol ester, Phosphorylation, Retinoic acid, gamma-secretase
Nationell ämneskategori
Biokemi och molekylärbiologi
Forskningsämne
neurokemi med molekylär neurobiologi
Identifikatorer
urn:nbn:se:su:diva-127350 (URN)10.1016/j.neulet.2015.12.050 (DOI)000369463200010 ()26742640 (PubMedID)
Tillgänglig från: 2016-03-11 Skapad: 2016-03-02 Senast uppdaterad: 2022-02-23Bibliografiskt granskad
Tracy, L., Bergqvist, F., Ivanova, E., Jacobsen, K. & Iverfeldt, K. (2013). Exposure to the Saturated Free Fatty Acid Palmitate AltersBV-2 Microglia Inflammatory Response. Journal of Molecular Neuroscience, 51(3), 805-812
Öppna denna publikation i ny flik eller fönster >>Exposure to the Saturated Free Fatty Acid Palmitate AltersBV-2 Microglia Inflammatory Response
Visa övriga...
2013 (Engelska)Ingår i: Journal of Molecular Neuroscience, ISSN 0895-8696, E-ISSN 1559-1166, Vol. 51, nr 3, s. 805-812Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Elevated levels of free fatty acids (FFAs) in plasma and increased incidence of chronic systemic inflammation are associated with obesity. In the brain, activated microglia are believed to play different roles during inflammation that may either be neuroprotective or promote neurodegeneration. Here, we have investigated the effects of FFAs on microglial response to inflammatory stimuli. Our results indicate that the saturated FFA palmitate on its own induces alternative activation of BV-2 microglia cells. Further, pre-exposure to palmitate changed the response of microglia to lipopolysaccharide (LPS). We show that palmitate affects the mRNA levels of the pro-inflammatory cytokines interleukin-1β and interleukin-6. The transcription factor CCAAT/enhancer-binding protein δ is also affected by pre-exposure to palmitate. Furthermore, the phagocytic activity of microglia was investigated using fluorescent beads. By analyzing the bead uptake by fluorescence-activated cell sorting, we found that palmitate alone, as well as together with LPS, stimulated the phagocytic activity of microglia. Taken together, our results suggest that exposure of microglia to increased levels of free fatty acids may alter the consequences of classical inflammatory stimuli.

Nationell ämneskategori
Biokemi och molekylärbiologi Neurovetenskaper
Identifikatorer
urn:nbn:se:su:diva-95103 (URN)10.1007/s12031-013-0068-7 (DOI)000325710500021 ()
Tillgänglig från: 2013-10-21 Skapad: 2013-10-21 Senast uppdaterad: 2022-02-24Bibliografiskt granskad
Kappe, C., Tracy, L. M., Patrone, C., Iverfeldt, K. & Sjöholm, Å. (2012). GLP 1 secretion by microglial cells and decreased cns expression in obesity. Journal of Neuroinflammation, 9, 276
Öppna denna publikation i ny flik eller fönster >>GLP 1 secretion by microglial cells and decreased cns expression in obesity
Visa övriga...
2012 (Engelska)Ingår i: Journal of Neuroinflammation, ISSN 1742-2094, E-ISSN 1742-2094, Vol. 9, s. 276-Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Type 2 diabetes (T2D) is a strong risk factor for developing neurodegenerative pathologies. T2D patients have a deficiency in the intestinal incretin hormone GLP-1, which has been shown to exert neuroprotective and anti-inflammatory properties in the brain. Methods: Here we investigate potential sources of GLP-1 in the CNS and the effect of diabetic conditions on the proglucagon mRNA expression in the CNS. The obese mouse model ob/ob, characterized by its high levels of free fatty acids, and the microglia cell line BV-2 were used as models. mRNA expression and protein secretion were analyzed by qPCR, immunofluorescence and ELISA. Results: We show evidence for microglia as a central source of GLP-1 secretion. Furthermore, we observed that expression and secretion are stimulated by cAMP and dependent on microglial activation state. We also show that insulin-resistant conditions reduce the central mRNA expression of proglucagon. Conclusion: The findings that microglial mRNA expression of proglucagon and GLP-1 protein expression are affected by high levels of free fatty acids and that both mRNA expression levels of proglucagon and secretion levels of GLP-1 are affected by inflammatory stimuli could be of pathogenic importance for the premature neurodegeneration and cognitive decline commonly seen in T2D patients, and they may also be harnessed to advantage in therapeutic efforts to prevent or treat such disorders.

Nyckelord
Glucagon-like peptide-1, Microglia, Neuroinflammation, Neuroprotection, Proglucagon
Nationell ämneskategori
Neurovetenskaper
Identifikatorer
urn:nbn:se:su:diva-88298 (URN)10.1186/1742-2094-9-276 (DOI)000314754300001 ()
Anmärkning

AuthorCount:5;

Tillgänglig från: 2013-03-20 Skapad: 2013-03-12 Senast uppdaterad: 2022-03-23Bibliografiskt granskad
Darsalia, V., Mansouri, S., Ortsater, H., Olverling, A., Nozadze, N., Kappe, C., . . . Patrone, C. (2012). Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clinical Science, 122(9-10), 473-483
Öppna denna publikation i ny flik eller fönster >>Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats
Visa övriga...
2012 (Engelska)Ingår i: Clinical Science, ISSN 0143-5221, E-ISSN 1470-8736, Vol. 122, nr 9-10, s. 473-483Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Diabetes is a strong risk factor for premature and severe stroke. The GLP-IR (glucagon-like peptide-1 receptor) agonist Ex-4 (exendin-4) is a drug for the treatment of T2D (Type 2 diabetes) that may also have neuroprotective effects. The aim of the present study was to determine the efficacy of Ex-4 against stroke in diabetes by using a diabetic animal model, a drug administration paradigm and a dose that mimics a diabetic patient on Ex-4 therapy. Furthermore, we investigated inflammation and neurogenesis as potential cellular mechanisms underlying the Ex-4 efficacy. A total of seven 9-month-old Type 2 diabetic Goto-Kakizaki rats were treated peripherally for 4 weeks with Ex-4 at 0.1, 1 or 5 mu g/kg of body weight before inducing stroke by transient middle cerebral artery occlusion and for 2-4 weeks thereafter. The severity of ischaemic damage was measured by evaluation of stroke volume and by stereological counting of neurons in the striatum and cortex. We also quantitatively evaluated stroke-induced inflammation, stem cell proliferation and neurogenesis. We show a profound anti-stroke efficacy of the clinical dose of Ex-4 in diabetic rats, an arrested microglia infiltration and an increase of stroke-induced neural stem cell proliferation and neuroblast formation, while stroke-induced neurogenesis was not affected by Ex-4. The results show a pronounced anti-stroke, neuroprotective and anti-inflammatory effect of peripheral and chronic Ex-4 treatment in middle-aged diabetic animals in a preclinical setting that has the potential to mimic the clinical treatment. Our results should provide strong impetus to further investigate GLP-IR agonists for their neuroprotective action in diabetes, and for their possible use as anti-stroke medication in non-diabetic conditions.

Nyckelord
exendin-4 (Ex-4), Goto-Kakizaki (GK) rat, middle cerebral artery occlusion (MCAO), neurogenesis, neuroprotection
Nationell ämneskategori
Biomedicinsk laboratorievetenskap/teknologi
Identifikatorer
urn:nbn:se:su:diva-80062 (URN)10.1042/CS20110374 (DOI)000303548900008 ()
Anmärkning

AuthorCount:11;

Tillgänglig från: 2012-09-27 Skapad: 2012-09-12 Senast uppdaterad: 2022-03-23Bibliografiskt granskad
Gatsinzi, T., Ivanova, E. V. & Iverfeldt, K. (2012). TRAIL resistance in human neuroblastoma SK-N-AS cells is dependent on protein kinase C and involves inhibition of caspase-3 proteolytic processing. Journal of Neuro-Oncology, 109(3), 503-512
Öppna denna publikation i ny flik eller fönster >>TRAIL resistance in human neuroblastoma SK-N-AS cells is dependent on protein kinase C and involves inhibition of caspase-3 proteolytic processing
2012 (Engelska)Ingår i: Journal of Neuro-Oncology, ISSN 0167-594X, E-ISSN 1573-7373, Vol. 109, nr 3, s. 503-512Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Neuroblastoma is the most common solid extracranial cancer form in childhood with an etiology that is mostly unknown. Although tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been proposed as a promising future anticancer drug candidate, highly malignant neuroblastoma has been reported to acquire TRAIL resistance by mechanisms that are poorly understood. Here, we show by western blot analysis, and live cell imaging using anchored FRET sensors, that the resistance to TRAIL-induced apoptosis in human neuroblastoma SK-N-AS cells depends on an incomplete processing of procaspase-3, generating an immature and catalytically inactive 21 kDa fragment. We have previously shown that the naturally occurring compound curcumin can sensitize SK-N-AS cells to TRAIL. In the present study, we show that curcumin also has a similar effect on human neuroblastoma SHEP1 cells. Furthermore, we show that curcumin and TRAIL co-treatment induces complete maturation and activation of caspase-3 in both cell lines. The mechanisms behind this effect seem to be dependent on protein kinase C (PKC), since inhibition of PKC using bisindolylmaleimide XI, could also sensitize these cells to TRAIL through a similar effect on caspase-3 activation. Moreover, TRAIL co-treatment with bisindolylmaleimide XI or curcumin resulted in down-regulation of X-linked inhibitor of apoptosis protein. In conclusion, our study shows that PKC can be involved in TRAIL resistance in human neuroblastoma cells by preventing caspase-3 maturation.

Nyckelord
AFS, Caspases, Curcumin, Neuroblastoma, PKC, TRAIL
Nationell ämneskategori
Biologiska vetenskaper
Forskningsämne
neurokemi med molekylär neurobiologi
Identifikatorer
urn:nbn:se:su:diva-79146 (URN)10.1007/s11060-012-0932-2 (DOI)000308441700007 ()22798207 (PubMedID)
Forskningsfinansiär
Vetenskapsrådet
Tillgänglig från: 2012-08-28 Skapad: 2012-08-28 Senast uppdaterad: 2022-02-24Bibliografiskt granskad
Figueroa, R. A., Ramberg, V., Gatsinzi, T., Samuelsson, M., Zhang, M., Iverfeldt, K. & Hallberg, E. (2011). Anchored FRET sensors detect local caspase activation prior to neuronal degeneration. Molecular Neurodegeneration, 6, 35
Öppna denna publikation i ny flik eller fönster >>Anchored FRET sensors detect local caspase activation prior to neuronal degeneration
Visa övriga...
2011 (Engelska)Ingår i: Molecular Neurodegeneration, E-ISSN 1750-1326, Vol. 6, s. 35-Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

BACKGROUND: Recent studies indicate local caspase activation in dendrites or axons during development and in neurodegenerative disorders such as Alzheimer's disease (AD). Emerging evidences point to soluble oligomeric amyloid-beta peptide as a causative agent in AD.

RESULTS: Here we describe the design of fluorescence resonance energy transfer (FRET)-based caspase sensors, fused to the microtubule associated protein tau. Specific caspase sensors preferentially cleaved by caspase-3, -6 or -9 were expressed in differentiated human neuroblastoma SH-SY5Y cells. The anchoring of the sensors resulted in high FRET signals both in extended neurites and soma and made analysis of spatiotemporal signal propagation possible. Caspase activation was detected as loss of FRET after exposure to different stimuli. Interestingly, after staurosporine treatment caspase-6 activation was significantly delayed in neurites compared to cell bodies. In addition, we show that exposure to oligomer-enriched amyloid-beta peptide resulted in loss of FRET in cells expressing sensors for caspase-3 and -6, but not -9, in both soma and neurites before neurite degeneration was observed.

CONCLUSIONS: Taken together, the results show that by using anchored FRET sensors it is possible to detect stimuli-dependent differential activation of caspases and to distinguish local from global caspase activation in live neuronal cells. Furthermore, in these cells oligomer-enriched amyloid-beta peptide induces a global, rather than local activation of caspase-3 and -6, which subsequently leads to neuronal cell death.

Nyckelord
Amyloid-beta, Caspases, FRET, Live Cell Imaging, Neurite degeneration, Neurodegeneration, Spatiotemporal analysis
Nationell ämneskategori
Biologiska vetenskaper Kemi
Forskningsämne
biokemi; neurokemi och neurotoxikologi; neurokemi med molekylär neurobiologi
Identifikatorer
urn:nbn:se:su:diva-58646 (URN)10.1186/1750-1326-6-35 (DOI)000291991900001 ()21605370 (PubMedID)
Forskningsfinansiär
Vetenskapsrådet, 2010-4481Vetenskapsrådet, 2010-4505
Tillgänglig från: 2011-06-07 Skapad: 2011-06-07 Senast uppdaterad: 2023-03-03Bibliografiskt granskad
Jacobsen, K. T. & Iverfeldt, K. (2011). O-GlcNAcylation increases non-amyloidogenic processing of the amyloid-beta precursor protein (APP). Biochemical and Biophysical Research Communications - BBRC, 404(3), 882-886
Öppna denna publikation i ny flik eller fönster >>O-GlcNAcylation increases non-amyloidogenic processing of the amyloid-beta precursor protein (APP)
2011 (Engelska)Ingår i: Biochemical and Biophysical Research Communications - BBRC, ISSN 0006-291X, E-ISSN 1090-2104, Vol. 404, nr 3, s. 882-886Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

The amyloid-beta precursor protein (APP) was shown to be O-GlcNAcylated 15 years ago, but the effect of this modification on APP processing and formation of the Alzheimer's disease associated amyloid-beta (A beta) peptide has so far not been investigated. Here, we demonstrate with pharmacological tools or siRNA that O-GlcNAcase and O-GlcNAc transferase regulate the level of O-GlcNAcylated APP. We also show that O-GlcNAcylation increases non-amyloidogenic alpha-secretase processing, resulting in increased levels of the neuroprotective sAPP alpha fragment and decreased A beta secretion. Our results implicate O-GlcNAcylation as a potential therapeutic target for Alzheimer's disease.

Nyckelord
Alzheimer's disease, Amyloid-beta, APP processing, O-linked glycosylation, alpha-Secretase
Nationell ämneskategori
Biokemi och molekylärbiologi
Identifikatorer
urn:nbn:se:su:diva-67334 (URN)10.1016/j.bbrc.2010.12.080 (DOI)000286848100023 ()
Anmärkning

authorCount :2

Tillgänglig från: 2011-12-28 Skapad: 2011-12-28 Senast uppdaterad: 2022-02-24Bibliografiskt granskad
Organisationer
Identifikatorer
ORCID-id: ORCID iD iconorcid.org/0000-0002-0308-1964

Sök vidare i DiVA

Visa alla publikationer